Jump to content

Basmisanil

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 01:32, 25 January 2021 (Task 18 (cosmetic): eval 4 templates: hyphenate params (1×);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Basmisanil
Clinical data
Other namesRG-1662; RO5186582
ATC code
  • None
Identifiers
  • (1,1-Dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H20FN3O5S
Molar mass445.47 g·mol−1
3D model (JSmol)
  • CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4
  • InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3
  • Key:VCGRFBXVSFAGGA-UHFFFAOYSA-N

Basmisanil (INNTooltip International Nonproprietary Name; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.[1][2][3] As of June 2016, it is no longer studied.[4]

See also

References

  1. ^ Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". J. Alzheimers Dis. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
  2. ^ Hurley, Dan (2013). "Investigators Silence Trisomy 21 Chromosome in Human Down Syndrome Cells". Neurology Today. 13 (17): 14–15. doi:10.1097/01.NT.0000434604.55014.fd. ISSN 1533-7006.
  3. ^ Rudolph, Uwe; Jensen, Henrik Sindal; Nichol, Kathryn; Lee, Deborah; Ebert, Bjarke (2014). "Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α2- versus α1-GABAA–Receptor Complexes". PLOS ONE. 9 (2): e88456. doi:10.1371/journal.pone.0088456. ISSN 1932-6203. PMC 3922815. PMID 24533090.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. ^ Marly Chevrette. "Response to the Roche Clinical Trial for CLEMATIS". Retrieved 2016-06-28.

External links